Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 68 of 95, showing 5 Applications out of 474 total, starting on record 336, ending on 340

# Protocol No Study Title Investigator(s) & Site(s)

336.

ECCT/15/06/04   A5316
        A5316           Evaluating Pharmacokinetic Interactions with Vaginal Ring Contraceptives and Antiretroviral Therapy   
Principal Investigator(s)
1. Dr. Esther Mumbi Makanga Makanga
2. Dr. Victor Akelo Akelo
3. Dr.Victor O. Mudhune Mudhune
4. Dr. Kevin P. Cain Cain
Site(s) in Kenya
KEMRI- CDC
 
View

337.

ECCT/18/11/01   PrIMA
              PrEP Implementation for Mothers in Antenatal Care            
Principal Investigator(s)
1. Grace John-Stewart John-Stewart
2. Jared Baeten
Site(s) in Kenya
1. Homa Bay County - 10 sites (Homa Bay county)
2. Siaya County - 10 sites (Siaya county)
 
View

338.

ECCT/22/03/08   CVIA 092
    “ A Phase 3 Multicenter, Observer Blind, Randomized, Controlled Study to Evaluate Safety (Ages 6 Months to 45 Years) and Non-inferiority (Ages 9-12 Months) of Multi-dose and Single-dose Vial Formulations of EuTCV (Vi-CRM197 Typhoid Conjugate Vaccine) against Typbar TCV® and Lot-to-Lot Consistency of the Immune Response (Ages 9-12 Months) to Multi-dose Vial Formulation EuTCV in Healthy African Participants”.    
Principal Investigator(s)
1. Dr Lucy Koech Chepkurui Koech
Site(s) in Kenya
KEMRI/ KERICHO CRC
 
View

339.

ECCT/15/01/02  
      Study title  An observational pilot study to characterize the immune response  induced by the commercial Varicella Zoster Virus vaccine  Zostavax® (Merck) in healthy adult females in Nairobi, Kenya.  Clinical Phase IV      
Principal Investigator(s)
1. Prof Walter Jaoko Jaoko
Site(s) in Kenya
KAVI-INSTITUTE OF CLINICAL RESEARCH (KAVI-ICR)
 
View

340.

ECCT/22/02/02   The Women TAF-FTC Benchmark
    Safety and Pharmacokinetics of TAF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender women   
Principal Investigator(s)
1. Dr. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD Thika
 
View